Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
4.250
-0.030 (-0.70%)
Nov 21, 2024, 11:01 AM EST - Market open

Skye Bioscience Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
11.117.712.34.924.344.39
Upgrade
Research & Development
12.55.826.012.931.942.24
Upgrade
Operating Expenses
23.6213.5218.317.856.296.63
Upgrade
Operating Income
-23.62-13.52-18.31-7.85-6.29-6.63
Upgrade
Interest Expense
-1.62-0.91-0.67-0.77-0.71-1
Upgrade
Interest & Investment Income
2.350.10.02000
Upgrade
Other Non Operating Income (Expenses)
00-0.06-0.020.449.41
Upgrade
EBT Excluding Unusual Items
-22.89-14.33-19.02-8.64-6.561.78
Upgrade
Gain (Loss) on Sale of Assets
1.22-0.31----
Upgrade
Asset Writedown
0.05-0.41-0.46---
Upgrade
Other Unusual Items
--1.38-0.12--0.73
Upgrade
Pretax Income
-21.23-37.64-19.47-8.52-6.561.05
Upgrade
Income Tax Expense
0.0100.01000
Upgrade
Net Income
-21.24-37.64-19.48-8.52-6.561.05
Upgrade
Net Income to Common
-21.24-37.64-19.48-8.52-6.561.05
Upgrade
Shares Outstanding (Basic)
3072211
Upgrade
Shares Outstanding (Diluted)
3072211
Upgrade
Shares Change (YoY)
537.83%215.43%36.56%75.70%36.48%39.95%
Upgrade
EPS (Basic)
-0.72-5.37-8.77-5.24-7.111.95
Upgrade
EPS (Diluted)
-0.72-5.37-8.77-5.24-7.46-12.09
Upgrade
Free Cash Flow
-22.47-13.96-12.84-6.57-6.06-6.03
Upgrade
Free Cash Flow Per Share
-0.76-1.99-5.78-4.04-6.55-8.89
Upgrade
EBITDA
-23.46-13.4-18.2-7.81-6.29-6.63
Upgrade
D&A For EBITDA
0.150.120.110.0300
Upgrade
EBIT
-23.62-13.52-18.31-7.85-6.29-6.63
Upgrade
Effective Tax Rate
-----0.15%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.